That the finely tuned balance between XIAP and its antagonists is critical in determining the clinical outcome in cancer patients was demonstrated in an analysis of 187 gastric adenocarcinomas in which the expression levels of XIAP and its antagonising factors including SMAC and XAF1 were examined. Here, DIABLO is linked to gastric adenocarcinoma.